ACADIA Pharma Reports Top-Line Results From Phase 3 ENHANCE Trial Of Pimavanserin As Adjunctive Treatment For Patients With Schizophrenia: 'did not achieve statistical significance on the primary endpoint, but showed a consistent trend in improvement...'